Head to Head Comparison: Verrica Pharmaceuticals (VRCA) and The Competition

Verrica Pharmaceuticals (NASDAQ:VRCA) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Verrica Pharmaceuticals to related businesses based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Verrica Pharmaceuticals and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1	1	3	0	2.40
Verrica Pharmaceuticals Competitors	7819	13780	25790	1035	2.41

Verrica Pharmaceuticals currently has a consensus target price of $12.67, indicating a potential upside of 215.80%. As a group, “Pharmaceuticals” companies have a potential upside of 24.70%. Given Verrica Pharmaceuticals’ higher probable upside, equities research analysts plainly believe Verrica Pharmaceuticals is more favorable than its competitors.

Volatility & Risk

Verrica Pharmaceuticals has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals’ competitors have a beta of -0.05, meaning that their average stock price is 105% less volatile than the S&P 500.

Valuation and Earnings

This table compares Verrica Pharmaceuticals and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58 million	-$17.89 million	-2.40
Verrica Pharmaceuticals Competitors	$5.49 billion	$3.25 billion	553.77

Verrica Pharmaceuticals’ competitors have higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Verrica Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Verrica Pharmaceuticals Competitors	-2,393.16%	-220.83%	-16.11%

Institutional & Insider Ownership

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Verrica Pharmaceuticals competitors beat Verrica Pharmaceuticals on 7 of the 13 factors compared.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc. is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals. Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.